Suppliers and packagers for VALPROATE SODIUM

VALPROATE SODIUM

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Fresenius Kabi Usa	VALPROATE SODIUM	valproate sodium	INJECTABLE;INJECTION	076539	ANDA	Fresenius Kabi USA, LLC	63323-494-16	10 VIAL, SINGLE-DOSE in 1 TRAY (63323-494-16) / 5 mL in 1 VIAL, SINGLE-DOSE (63323-494-41)	2003-08-18
Fresenius Kabi Usa	VALPROATE SODIUM	valproate sodium	INJECTABLE;INJECTION	076539	ANDA	Fresenius Kabi USA, LLC	63323-494-05	10 VIAL, SINGLE-DOSE in 1 TRAY (63323-494-05) / 5 mL in 1 VIAL, SINGLE-DOSE (63323-494-01)	2003-08-18
Hikma Farmaceutica	VALPROATE SODIUM	valproate sodium	INJECTABLE;INJECTION	078523	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9637-10	10 VIAL, SINGLE-DOSE in 1 TRAY (0143-9637-10) / 5 mL in 1 VIAL, SINGLE-DOSE (0143-9637-01)	2013-04-15
Hikma Farmaceutica	VALPROATE SODIUM	valproate sodium	INJECTABLE;INJECTION	078523	ANDA	Hikma Pharmaceuticals USA Inc.	0143-9785-10	10 VIAL, SINGLE-DOSE in 1 CARTON (0143-9785-10) / 5 mL in 1 VIAL, SINGLE-DOSE (0143-9785-01)	2010-02-17
Sagent	VALPROATE SODIUM	valproate sodium	INJECTABLE;INJECTION	076295	ANDA	Sagent Pharmaceuticals	25021-797-05	10 VIAL in 1 CARTON (25021-797-05) / 5 mL in 1 VIAL	2024-12-01

Valproate Sodium Drug Product: Global Supplier Landscape Analysis

Last updated: February 19, 2026

This report analyzes the global supplier landscape for valproate sodium, a critical antiepileptic and mood-stabilizing drug. The analysis focuses on key manufacturers, their production capacities, regulatory standing, and market presence to inform R&D and investment strategies.

Who are the Primary Manufacturers of Valproate Sodium?

The manufacturing of valproate sodium is consolidated among a limited number of global entities, primarily located in Asia and Europe. These manufacturers cater to both the active pharmaceutical ingredient (API) and finished drug product markets.

• API Manufacturers:

  • Jubilant Pharmova Limited (India): A significant player with substantial API production capabilities. Their facilities adhere to stringent global regulatory standards.
  • Acme Formulation Pvt. Ltd. (India): Another key Indian producer, known for its scale and consistent supply.
  • Sanofi S.A. (France): While a major finished product marketer, Sanofi also has integrated API production for its internal needs and select external sales.
  • BASF SE (Germany): A chemical conglomerate with a pharmaceutical ingredients division that produces valproate sodium API.
  • Haisco Pharmaceutical Group Co., Ltd. (China): A prominent Chinese manufacturer with increasing global reach for its APIs.

• Finished Drug Product Manufacturers: These entities utilize APIs from the above or their own integrated production to formulate and package valproate sodium into various dosage forms (tablets, capsules, solutions, injectables).

  • Aurobindo Pharma Ltd. (India): A large generic pharmaceutical company with a broad portfolio, including valproate sodium formulations.
  • Teva Pharmaceutical Industries Ltd. (Israel): A global leader in generic pharmaceuticals, with a significant presence in antiepileptic drugs.
  • Bausch Health Companies Inc. (Canada): Offers valproate sodium products in several markets.
  • Sun Pharmaceutical Industries Ltd. (India): Another major Indian generic drug manufacturer with valproate sodium products.
  • Mallinckrodt Plc (Ireland): Provides critical care and specialty pharmaceuticals, including valproate sodium injectables.

What is the Geographic Concentration of Valproate Sodium Production?

Production facilities for valproate sodium API and finished products are geographically concentrated, presenting both supply chain advantages and potential risks.

• India: Dominates API manufacturing due to cost efficiencies, established chemical synthesis expertise, and a large skilled workforce. Approximately 60% of global valproate sodium API production is estimated to originate from India.
• China: A growing contributor to API supply, with increasing investment in regulatory compliance and manufacturing scale.
• Europe (primarily France, Germany): Home to established pharmaceutical companies with integrated production, often focusing on higher-value or specialized formulations and serving domestic markets.
• United States: Primarily a market for finished drug products, with limited domestic API manufacturing for valproate sodium compared to Asian producers.

What are the Key Regulatory Approvals and Compliance Standards?

Manufacturers must adhere to rigorous regulatory standards to ensure the quality, safety, and efficacy of valproate sodium products. Key regulatory bodies and their requirements include:

• U.S. Food and Drug Administration (FDA): Requires Current Good Manufacturing Practices (cGMP) compliance for all API and finished product manufacturers supplying the U.S. market. Inspections and site audits are mandatory.
• European Medicines Agency (EMA): Oversees drug approvals and manufacturing standards (EU GMP) for member states. Similar inspection protocols are in place.
• Pharmaceuticals and Medical Devices Agency (PMDA) of Japan: Sets stringent quality and manufacturing requirements for products sold in Japan.
• Other National Regulatory Authorities: (e.g., Health Canada, Therapeutic Goods Administration Australia, CDSCO India) Each has its own set of guidelines and approval processes that manufacturers must satisfy for market access.

Manufacturers typically hold Drug Master Files (DMFs) or Certificates of Suitability to the monographs of the European Pharmacopoeia (CEP) for their APIs, which are reviewed by regulatory agencies as part of drug product applications.

What is the Current Market Supply and Demand Outlook?

The global demand for valproate sodium remains stable, driven by its established efficacy in treating epilepsy, bipolar disorder, and migraine prophylaxis.

• Demand Drivers:

  • Prevalence of epilepsy, which affects an estimated 50 million people worldwide [1].
  • Increasing diagnosis and management of bipolar disorder.
  • Use as a migraine preventative, although newer treatments are emerging.
  • Cost-effectiveness compared to newer antiepileptic drugs, particularly in emerging markets.

• Supply Dynamics:

  • API Availability: Generally stable, with India and China acting as primary global suppliers. Potential for supply chain disruptions exists due to geopolitical factors or localized production issues, as witnessed with other APIs.
  • Finished Product Availability: Robust, with numerous generic manufacturers competing in major markets. Sanofi's brand-name product (Depakote, Epilim) maintains a significant market share, especially in developed countries.
  • Capacity Utilization: API manufacturers operate at varying capacity utilization rates, with flexibility to scale up based on demand shifts. Finished product manufacturers adjust production based on market orders and inventory levels.

What are the Key Quality and Manufacturing Considerations?

Manufacturing valproate sodium requires meticulous control over chemical synthesis and formulation to ensure product purity and stability.

• API Synthesis:

  • Key Reactions: Typically involves the synthesis of valeric acid, followed by reaction with ammonia or sodium hydroxide.
  • Impurity Profiling: Strict control over residual solvents, heavy metals, and process-related impurities is critical. ICH Q3A and Q3C guidelines are paramount.
  • Polymorphism: Valproic acid and its salts can exhibit polymorphism, requiring controlled crystallization processes to ensure consistent physical form and dissolution properties.

• Finished Product Formulation:

  • Dosage Forms: Available as immediate-release tablets, extended-release tablets, capsules, oral solutions, and intravenous solutions.
  • Excipient Compatibility: Careful selection of excipients to ensure compatibility with valproate sodium and to achieve desired release profiles.
  • Stability Studies: Comprehensive stability testing under ICH Q1A(R2) conditions is required to establish shelf life.

What are the Competitive and Strategic Implications for Stakeholders?

The valproate sodium market, while mature, presents strategic considerations for R&D and investment.

• Generic Competition: Intense competition among generic manufacturers can lead to price erosion, necessitating efficient manufacturing and supply chain management.
• API Sourcing Strategy: Diversifying API suppliers across different geographies (e.g., India and China, or India and a European supplier) can mitigate supply chain risks. Establishing long-term contracts with key API manufacturers is advisable.
• Differentiated Formulations: Opportunities exist for developing novel or improved valproate sodium formulations, such as extended-release technologies with enhanced patient compliance or reduced side effects.
• Regulatory Navigation: Manufacturers must maintain up-to-date regulatory filings and be prepared for ongoing inspections, particularly for global market access.
• Emerging Markets: Growing demand in emerging economies presents opportunities, but requires understanding local regulatory pathways and pricing sensitivities.

What is the Intellectual Property Landscape?

The primary patents protecting the original valproate sodium molecule and its early applications have long expired. Current intellectual property focuses on:

• Formulation Patents: Protecting specific extended-release technologies, novel excipient combinations, or improved methods of manufacturing finished dosage forms.
• Method of Use Patents: Covering new therapeutic indications or specific patient populations for valproate sodium.
• Polymorph Patents: Claims on specific crystalline forms of valproate sodium that offer improved stability or bioavailability.

A thorough patent landscape analysis is crucial before initiating R&D on new valproate sodium products or entering the market with generic formulations.

Key Takeaways

• Valproate sodium API production is concentrated in India and China, with established European and U.S. companies focused on finished product manufacturing and marketing.
• Regulatory compliance, including cGMP standards from FDA, EMA, and other national bodies, is a critical barrier to entry and a continuous operational requirement.
• The market is characterized by stable demand driven by its efficacy in neurological and psychiatric disorders, alongside significant generic competition.
• Strategic considerations involve supply chain diversification, potential for formulation innovation, and navigating the evolving intellectual property landscape.

Frequently Asked Questions

1. What is the typical lead time for securing a new API supply contract for valproate sodium from a major Indian manufacturer? Lead times can range from 6 to 12 months, depending on the manufacturer's current production schedules, existing contractual obligations, and the volume required. It also depends on the thoroughness of the qualification process, which may include site audits and quality agreement finalization.

2. Are there significant supply chain risks associated with relying heavily on a single API manufacturer for valproate sodium? Yes, significant risks exist. These include production interruptions due to quality issues, facility shutdowns, geopolitical instability, or natural disasters. Diversifying suppliers across different geographic regions is a recommended mitigation strategy.

3. What are the main differences in regulatory requirements for valproate sodium API versus finished drug product when supplying to the U.S. market? For API, manufacturers must typically file a Drug Master File (DMF) with the FDA and ensure their facilities comply with U.S. cGMP. Finished drug product manufacturers must submit an Abbreviated New Drug Application (ANDA) that references the API's DMF and demonstrates compliance with cGMP for their own formulation, manufacturing, and packaging processes.

4. Does the emergence of newer antiepileptic drugs significantly impact the demand for valproate sodium? While newer drugs offer alternative treatment options and may be preferred for specific patient profiles due to differing side effect profiles or efficacy in certain seizure types, valproate sodium remains a first-line or adjunctive therapy for many epilepsy and bipolar disorder patients. Its established efficacy, broad spectrum of action, and cost-effectiveness, particularly in emerging markets, ensure continued demand.

5. What is the average purity level required for valproate sodium API by regulatory agencies? Regulatory agencies such as the FDA and EMA, along with pharmacopeias (e.g., USP, EP), typically require valproate sodium API purity to be at least 98.0% and not more than 102.0% on an anhydrous basis, with stringent limits on specific impurities, residual solvents, and heavy metals. Manufacturers must demonstrate consistent adherence to these specifications.

Citations

[1] World Health Organization. (2021). Epilepsy. Retrieved from https://www.who.int/news-room/fact-sheets/detail/epilepsy